HC Wainwright Issues Positive Estimate for Zura Bio Earnings

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Investment analysts at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for shares of Zura Bio in a research note issued on Monday, May 19th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.19) per share for the quarter, up from their prior forecast of ($0.21). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Zura Bio's Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS and FY2025 earnings at ($0.76) EPS.

Several other equities research analysts also recently commented on the stock. Oppenheimer dropped their price objective on shares of Zura Bio from $19.00 to $17.00 and set an "outperform" rating on the stock in a report on Friday, May 9th. Guggenheim restated a "buy" rating and set a $15.00 price target on shares of Zura Bio in a research note on Wednesday, March 26th. Finally, Chardan Capital reduced their price objective on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, March 26th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Zura Bio has an average rating of "Buy" and a consensus target price of $14.33.

Zura Bio Trading Down 1.9%

Shares of ZURA stock traded down $0.02 on Wednesday, hitting $1.02. 293,130 shares of the stock were exchanged, compared to its average volume of 410,534. The firm's 50 day moving average is $1.25 and its two-hundred day moving average is $1.84. Zura Bio has a one year low of $0.97 and a one year high of $5.56. The firm has a market capitalization of $69.74 million, a PE ratio of -1.46 and a beta of 0.05.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02).

Institutional Investors Weigh In On Zura Bio

Several large investors have recently added to or reduced their stakes in ZURA. American Century Companies Inc. bought a new position in Zura Bio in the 4th quarter worth about $27,000. Prudential Financial Inc. purchased a new position in shares of Zura Bio during the fourth quarter worth about $28,000. Two Sigma Advisers LP bought a new position in shares of Zura Bio in the fourth quarter worth approximately $32,000. ProShare Advisors LLC purchased a new stake in Zura Bio in the fourth quarter valued at approximately $35,000. Finally, XTX Topco Ltd purchased a new stake in Zura Bio in the fourth quarter valued at approximately $44,000. Institutional investors own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.